Telehealth sprouted up with the COVID-19 pandemic and now it's spreading more, serving people seeking narrower waistlines ...

(NEXSTAR) – GLP-1 drugs, which have grown incredibly popular in recent years for their ability to help people lose substantial weight, are now friendlier to needle-phobes. The class of medications, ...

Nearly a year after CVS Caremark dropped Eli Lilly's blockbuster Zepbound from its standard coverage plan, causing anxiety for thousands of patients and prescribers, the pharmacy benefit manager ...

Eli Lilly’s stock closed at a record high after the drugmaker disclosed that one of the nation’s most powerful pharmacy-benefit managers will start covering its popular GLP-1 medications later this ...

CVS Health announced it will reinstate coverage of Eli Lilly's blockbuster weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo for millions of Americans on private ...

CVS Caremark is reversing course a year after it removed the obesity drug Zepbound from its formularies. The nation’s largest pharmacy benefits manager said it will add Zepbound back to ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered medications last year, drugmaker Eli Lilly said Thursday. CVS Caremark is one of ...

More than 10 million US patients will regain easy access to Eli Lilly & Co.’s obesity shot Zepbound through insurance after CVS Health Corp. reversed a controversial decision to restrict it for ...

All major US pharmacy benefit managers now cover Lilly's obesity treatments CVS includes Foundayo as a co-preferred weight-loss drug starting Monday It will restart Zepbound coverage on October 1 Sign ...

CVS Health said it will restore coverage of Eli Lilly's blockbuster weight loss injection Zepbound and start covering its new obesity pill on its standard drug plans. The move supports Lilly's efforts ...